ORION Biotech Catalyst Calendar
Menu
Skip to company dates

Jasper Therapeutics (JSPR) pipeline and stated timing

Name in SEC filings: Jasper Therapeutics, Inc.

Pipeline at a glance

ProgramEventStageStated timingFiling
KP-104 (vensobafusp alfa)/data readoutPhase 2fourth quarter of 20268-K ·
KP-104 (vensobafusp alfa)Topline/data readoutPhase 2second quarter of 202710-Q ·
KP-104 (vensobafusp alfa)Topline/data readoutStage not statedsecond quarter of 202710-Q ·

Source: ORION, orionbiotechai.com/company/JSPR, data as of Oct 13, 2026
https://www.orionbiotechai.com/company/JSPR

Nearest upcoming stated timing: KP-104 (vensobafusp alfa) · Topline/data readout · fourth quarter of 2026

SEC sources last checked .

Programs and stated timing

○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.

KP-104 (vensobafusp alfa)

Matched

Topline/data readoutfourth quarter of 2026

Stage: Phase 2SEC filing · “Phase 2”

Public float: $74,800,000 · as of · SEC filing

KP-104 is currently being evaluated in a Phase 2 basket trial in rare renal indications and interim data from Stage 1 of the trial is expected in the fourth quarter of 2026.

8-K · Filed · Last checked

Source details

Accession 0001213900-26-090055

Alert me · Calendar: same stage and window-end month (2026-12)

KP-104 (vensobafusp alfa)

Matched

Topline/data readoutsecond quarter of 2027

Stage: Phase 2SEC filing · “Phase 2”

Public float: $74,800,000 · as of · SEC filing

We expect to report interim data from Stage 1 of the ongoing Phase 2 basket trial in the fourth quarter of 2026 and updated data in the second quarter of 2027

10-Q · Filed · Last checked

Source details

Accession 0001213900-26-089592

Alert me · Calendar: same stage and window-end month (2027-06)

KP-104 (vensobafusp alfa)

Matched

Topline/data readoutsecond quarter of 2027

Stage: Not stated

Public float: $74,800,000 · as of · SEC filing

we plan to report interim data from Stage 2 of the study in the second quarter of 2027.

10-Q · Filed · Last checked

Source details

Accession 0001213900-26-089592

Alert me · Calendar: same stage and window-end month (2027-06)

How this date was described over time

Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .

Program / eventStated period and SEC wordingDisclosure in stated period
KP-104 (vensobafusp alfa)Clinical resultsfourth quarter of 2026
“KP-104 is currently being evaluated in a Phase 2 basket trial in rare renal indications and interim data from Stage 1 of the trial is expected in the fourth quarter of 2026.”

Filed · EX-99.1

Still within period

As of Oct 19, 2026

KP-104 (vensobafusp alfa)Clinical resultssecond quarter of 2027
“We expect to report interim data from Stage 1 of the ongoing Phase 2 basket trial in the fourth quarter of 2026 and updated data in the second quarter of 2027”

Filed · 10-Q

Period not started

The stated period has not started yet, so there is nothing to compare.

KP-104 (vensobafusp alfa)Clinical resultssecond quarter of 2027
“we plan to report interim data from Stage 2 of the study in the second quarter of 2027.”

Filed · 10-Q

Period not started

The stated period has not started yet, so there is nothing to compare.

KP-104 (vensobafusp alfa)Clinical resultsfourth quarter of 2026
“The Combined Company expects to report interim data from Stage 1 of the ongoing Phase 2 basket trial in rare renal indications in the fourth quarter of 2026, and updated data in the second quarter of 2027.”

Filed · EX-99.1

Still within period

As of Oct 19, 2026

KP-104 (vensobafusp alfa)Clinical resultssecond quarter of 2027
“The Combined Company expects to report interim data from Stage 1 of the ongoing Phase 2 basket trial in rare renal indications in the fourth quarter of 2026, and updated data in the second quarter of 2027.”

Filed · EX-99.1

Period not started

The stated period has not started yet, so there is nothing to compare.

KP-104 (vensobafusp alfa)Clinical resultssecond quarter of 2027
“Additionally, the Combined Company plans to report interim data from Stage 2 of the study in the second quarter of 2027.”

Filed · EX-99.1

Period not started

The stated period has not started yet, so there is nothing to compare.

“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.

Watch JSPR

Or email ORION to ask for this Watch.

Request another SEC timing statement

Suggest an SEC timing statement to add for JSPR. You can include the original filing link in your note. The founder reads each request by hand.

Or email ORION.

Reading these records

First stated window
The timing wording in the earliest company statement located within the sources checked, quoted as written (for example “2H 2026”). An earlier statement may exist outside those sources.
Disclosure date
The date of the filing or company release that disclosed the readout. “None found” means no such disclosure was located in the sources checked. SEC filings were searched through the “SEC filings searched through” date shown.
1H, 2H, 1Q–4Q
First or second half, or first to fourth quarter, of the year named, as the company wrote it. Equivalent notations are compared together; the original wording stays visible.
SEC original
The filing as published on the SEC EDGAR system. “Company original” is the release on the company's own investor site.
Status
One of seven labels set by founder review of the original filings. Definitions: Methodology.

See JSPR in the calendar · Review labels and methodology

Topline results are the main summary results of a clinical trial, released before the full data.